Tag: Immunotherapy
FDA Approves Immunotherapy for dMMR Endometrial Cancer
Jemperli approved for dMMR endometrial cancer that progressed after platinum-containing chemotherapy treatment
Cutaneous AEs Linked to Immune Checkpoint Inhibitor Therapy
Cutaneous immune-related adverse events seen in 25 percent of cancer patients initiating ICI therapy with median onset time of 113 days
Chronic Adverse Effects From Anti-PD-1 Immunotherapies Common
About 43 percent of patients who receive anti-PD1 therapy for advanced melanoma have chronic immune-related adverse effects
Broadly Neutralizing Antibodies Do Not Prevent Overall HIV-1 Acquisition
Analysis of pooled data from proof-of-concept trials shows bnAb VRC01 does reduce incidence of infection with VRC01-sensitive isolates
Early Immunologic Biomarker Predicts Renal Allograft Outcomes
Ratio of IL-10/TNFα produced by T1B three months after renal transplantation predicts clinical, subclinical rejection during first year
Fecal Transplant May Counter Anti-PD-1 Resistance in Melanoma
FMT plus anti-PD-1 therapy may change gut microbiome and help overcome drug resistance in some patients with advanced melanoma
SARS-CoV-2 Infection Rate Low in Patients Receiving Antitumor Therapy
Less than 1 percent of patients receiving antitumor treatment between Jan. 15 and May 4, 2020, developed COVID-19
Maintenance Peanut Oral Immunotherapy Effective for Preschoolers
Majority of children reach tolerance great enough to protect them from accidental exposure to peanuts
Genetic Ancestry Tied to Lung Cancer Mutations in Latin Americans
Mutation frequencies of EGFR and KRAS were 30 and 10 percent, respectively, and 23 and 13 percent, respectively, for Mexican and Colombian patients
ASH: CAR T-Cell Therapy Promising for Relapsed/Refractory iNHL
Phase 2 study reveals high objective response rate for CAR T-cell therapy in patients with follicular lymphoma, marginal zone lymphoma
